Stages II-III Multiple Myeloma


References (March 9, 2017)

1 Alexanian R, Dimopoulos M. The treatment of multiple myeloma. New England Journal of Medicine. 1994;330:484-489. 2 Barlogie B, Kyle RA, Anderson KC et al. Standard chemotherapy compared with high-dose... Continue Reading

Velcade® Revlimid®/Dexamethasone New Standard of Care for Newly Diagnosed Multiple Myeloma (January 31, 2017)

The addition of the proteasome inhibitor Velcade® (bortezomib) to the treatment combination Revlimid® (lenalidomide) plus dexamethasone improves survival when used as initial therapy in multiple myeloma... Continue Reading

Darzalex® Approved for Additional Indications in Multiple Myeloma (November 29, 2016)

The United States Food and Drug Administration (FDA) has approved Darzalex® (daratumumab) for the treatment of multiple myeloma among patients who have received at least one prior therapy. The new FDA... Continue Reading

Darzalex™ Effective in Heavily Pre-Treated Multiple Myeloma (July 7, 2016)

The targeted agent Darzalex (daratumumab) produces long-lasting anti-cancer responses among patients with multiple myeloma that has stopped responding to several prior therapies. These results were recently... Continue Reading

News Briefing in St. Louis on May 24 Addressing the Impact of ICER’S “Value” Determinations for New Multiple Myeloma Therapies (May 24, 2016)

News Conference Will Be Live Streamed RIGHT HERE at: 11 AM EDT; 10 AM CDT To Register Your Attendance: CLICK HERE In advance of the Institute for Clinical and Economic Research’s (ICER) plan to debate... Continue Reading

Ask the Expert: Multiple Myeloma (May 4, 2016)

CancerConnect recently collaborated with The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute (OSUCCC – James) to provide you with the opportunity... Continue Reading

Have a Question about Multiple Myeloma? Join us on April 28th (April 26, 2016)

CancerConnect and The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute Will Present: Ask the Expert with Dr. Hofmeister CancerConnect in collaboration... Continue Reading

Farydak® Significantly Improves Outcomes for Heavily Pre-Treated Multiple Myeloma (March 10, 2016)

The addition of Farydak® (panobinostat) to the standard treatment combination consisting of Velcade® (bortezomib) and dexamethasone significantly improves progression-free survival among patients with... Continue Reading

Addition of Velcade® to Revlimid®/Dexamethasone Improves Survival in Newly Diagnosed Multiple Myeloma (December 15, 2015)

The addition of the proteasome inhibitor Velcade® (bortezomib) to the treatment combination Revlimid® (lenalidomide) plus dexamethasone improves survival when used as initial therapy in multiple myeloma... Continue Reading

National Multiple Myeloma Awareness Month on CancerConnect (March 3, 2015)

Sun Valley, ID & Fort Worth, TX– OMNI Health Media (OMNI) announces the launch of multiple myeloma educational programs for national multiple myeloma awareness month. As the month of March brings... Continue Reading

2014: Another Year of Research Progress in Multiple Myeloma (January 8, 2015)

After several years of developments in multiple myeloma treatment, 2014 continued. An investigational new class of drugs, the anti-CD38 monoclonal antibodies, could be the next major advance in the treatment... Continue Reading

SAR 650948 Anti-CD38 Monoclonal Antibody Appears Promising For the Treatment of Multiple Myeloma (December 9, 2014)

CancerConnect News: An investigational new class of drugs, the anti-CD38 monoclonal antibodies, could be the next major advance in the treatment of multiple myeloma. These findings were presented at the... Continue Reading

Investigational Oral Drug Combo Shows Promise for Newly Diagnosed Multiple Myeloma in Mayo Clinic-Led Study (December 8, 2014)

Doctors have reported that the investigational drug ixazomib which can be taken orally in combination with Revlimid (lenalidomide) and dexamethasone shows promise for the treatment of patients with newly... Continue Reading

Strategies to Improve Treatment (December 5, 2014)

Advances in precision medicine are leading to the development of more effective treatments for multiple myeloma.   Advances require that these new and innovative therapies be evaluated with cancer patients... Continue Reading

Managing Complications & Side Effects of Myeloma (December 5, 2014)

The treatment of multiple myeloma is focused on controlling the underlying disease (the increased number of abnormal plasma cells). Managing the symptoms and other medical problems resulting from the increased... Continue Reading

High-dose Therapy and Stem Cell Transplant (December 5, 2014)

A large, comparative, phase III clinical trial recently confirmed that upfront ASCT remains superior to novel agents for treatment of multiple myeloma and should still be the treatment of choice in younger... Continue Reading

Standard-Dose Induction Therapy for Multiple Myeloma (December 5, 2014)

Most patients with stage II or III multiple myeloma will initially receive treatment with standard-dose chemotherapy.  Doctors will increasingly be incorporating newer precision medicines in an attempt... Continue Reading

September Is National Blood Cancer Awareness Month (September 5, 2014)

Sun Valley, ID & Fort Worth, TX– OMNI Health Media (OMNI) announces the launch of blood cancer educational programs for national blood cancer awareness month. As the month of September brings blood... Continue Reading

Next Page »

Sign up for the CancerConnect newsletter

Sign up for our newsletter and receive the latest news and updates about specific types of cancer.

  Close |  Please don't show me this again

Facebook Twitter RSS